WuXi AppTec Group and Mayo Clinic announced a joint venture to co-develop and deliver clinical diagnostic services in China. With WuXi AppTec Group’s operational excellence and Mayo Medical Laboratories’ clinical and laboratory testing expertise, the new joint venture will accelerate the development of novel esoteric tests that both organizations will offer in their respective markets, with the intent to benefit not only patients in China but around the world.

“Through this agreement, WuXi AppTec Group will have access, through an exclusive partnership, to Mayo-developed tests and will be able to offer those tests to hospitals, health care providers, and patients in China,” says William Morice, II, M.D., Ph.D., president of Mayo Medical Laboratories and chair of Laboratory Medicine and Pathology at Mayo Clinic. “We expect this new venture to accelerate diagnostics research in our laboratory as well, transforming discoveries into tests that will benefit all patients.”

“We are excited to work with Mayo Clinic to bring a highly innovative, world-class diagnostics testing portfolio to China,” says Jason Liu, Ph.D., senior vice president of WuXi AppTec Group, and chief operating officer of the company’s laboratory testing division. “This collaboration is a great fit with our mission to bring the best testing solutions from research to clinical practice. As one of the most highly regarded medical institutions in the world, Mayo Clinic will help transform China’s diagnostic landscape, improve the quality of patient care, and accelerate precision medicine in China.”

“The strategic collaboration with Mayo Clinic is an important step forward to fulfill WuXi AppTec Group’s dream that every drug can be made, every disease can be treated,” says Dr. Ge Li,  chairman of WuXi AppTec Group. “Through the collaboration with Mayo, we’re committed to building a leading diagnostic services operation in China and co-developing in ways that will benefit our patients, doctors, and innovative collaborators in all corners of the world.”